SYNTHETIC MOLECULES APPLIED IN THE TREATMENT OF TYPE 2 DIABETES


Synthetic molecules applied in the treatment of type 2 diabetes


João Alberto Lins de Lima1, 2, Rafael Artur Queiroz Cavalcanti de Sá3, Viviane Ramos Bandeira3, Francisco Henrique da Silva3, Matheus Alves Siqueira de Assunção4, Fálba Bernadete Ramos dos Anjos4, Bárbara de Azevedo Ramos2

1Departent of Chemistry, Rural Federal University of Pernambuco; 2Department of Antibiotics, Federal University of Pernambuco,  Recife, Pernambuco, Brazil; 3Department of Biochemistry, Federal University of Pernambuco,  Recife, Pernambuco, Brazil; 4Department of Histology and Embryology, Federal University of Pernambuco,  Recife, Pernambuco, Brazil


International Research Journal of Diabetes and Metabolism

Diabetes is considered a multifactorial disease that afflicts populations of the most diverse classes worldwide, being among the main health problems today. Among the types of diabetes, type 2 diabetes mellitus (DM-2) is considered the most prevalent pathology. This is due to the direct relationship between the cause of this disease and people’s eating behavior. These factors justify the growing search for the development of drugs for DM-2, given that current drugs act on targets that are not very efficient for the treatment. Therefore, the objective of this review is to evaluate the progress of research related to the search for new synthetic drugs for a more selective treatment for DM-2. The researches were searched in the main academic databases (National Center for Biotechnology Information (NCBI), Science Direct and Google Scholar), and research tools such as Drug Bank and Clinical Trials. Seventy articles were selected that were causally related to the descriptors used. According to the survey, about 60 compounds of synthetic origin were found and present in the various phases of the study and some molecules already approved for use. A variety of strategies and new therapies related to DM-2 grows each year, as new targets involved are elucidated. Therefore, it is possible to envision a promising future for the treatment of DM-2. because studies like this show the evolution of biochemical research methods and the advances in medicinal chemistry, it will be possible in the future that a multifactorial disease of this type can be treated in a specific way for each patient.


Keywords:  Synthetic drugs, Type 2 Diabetes Mellitus, New treatment strategies.

Free Full-text PDF


How to cite this article:
João Alberto Lins de Lima, Rafael Artur Queiroz Cavalcanti de Sá, Viviane Ramos Bandeira, Francisco Henrique da Silva, Matheus Alves Siqueira de Assunção, Fálba Bernadete Ramos dos Anjos, Bárbara de Azevedo Ramos.Synthetic molecules applied in the treatment of type 2 diabetes.International Research Journal of Diabetes and Metabolism, 2020, 3:14.


References
1. SCHEEN, A. J. Pathophysiology of type 2 diabe-tes. Acta Clinica Belgica, v. 58, n. 6, p. 335-341, 2003.
2. RUBINO, Francesco et al. The mechanism of dia-betes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Annals of sur-gery, v. 244, n. 5, p. 741, 2006.
3. MERICAN DIABETES ASSOCIATION et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in dia-betes—2019. Diabetes care, v. 42, n. Supplement 1, p. S34-S45, 2019
4. OMS. Organização mundial da saúde. 2019.
5. PONTIROLI, A. E. Type 2 diabetes mellitus is be-coming the most common type of diabetes in school children. Acta diabetologica, v. 41, n. 3, p. 85-90, 2004.
6. FUJIWARA, T. Mary; BICHET, Daniel G. Molecular biology of hereditary diabetes insipidus. Journal of the American Society of Nephrology, v. 16, n. 10, p. 2836-2846, 2005.
7. BICHET, 2008
8. WILLSKY, Gail R. et al. Anti-diabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes. Coordination chemistry reviews, v. 255, n. 19-20, p. 2258-2269, 2011.
9. ROBERTSON, Gary L. Diabetes insipidus: differ-ential diagnosis and management. Best Practice & Research Clinical Endocrinology & Metabolism, v. 30, n. 2, p. 205-218, 2016.
10. NOLAN, J. J. et al. The cost of treating type 2 diabetes (CODEIRE). Irish medical journal, v. 99, n. 10, p. 307-310, 2006.
11. COSKUN, Tamer et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular metabolism, v. 18, p. 3-14, 2018.
12. OZOUGWU, J. C. et al. The pathogenesis and pathophysiology of type 1 and type 2 diabetes melli-tus. Journal of physiology and pathophysiology, v. 4, n. 4, p. 46-57, 2013.
13. MCLELLAN, Kátia Cristina Portero et al. Diabetes mellitus do tipo 2, síndrome metabólica e modificação no estilo de vida. Revista de Nutrição, v. 20, n. 5, p. 515-524, 2007.
14. PRADO, Wagner Luiz do et al. Obesidade e adipocinas inflamatórias: implicações práticas para a prescrição de exercício. Revista Brasileira de Medicina do Esporte, v. 15, n. 5, p. 378-383, 2009.
15. ARAÚJO et al 2002
16. GOMES, Bárbara Festa; ACCARDO, Camila de Melo. Mediadores imunoinflamatórios na patogênese do diabetes mellitus. Einstein (São Paulo), v. 17, n. 1, p. -, 2019.
17. KOBZAR, Oleksandr L. et al. Fullerene deriva-tives as a new class of inhibitors of protein tyrosine phosphatases. Bioorganic & medicinal chemistry let-ters, v. 24, n. 14, p. 3175-3179, 2014.
18. KIM, Seok-Ho et al. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Im-proves Glucose and Lipid Metabolism. Scientific re-ports, v. 9, n. 1, p. 1-12, 2019.
19. ITO, Yuma et al. Therapeutic effects of the allo-steric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via en-hancements in insulin and leptin signaling in mice. Journal of pharmacological sciences, v. 137, n. 1, p. 38-46, 2018.
20. ZHONG, et al. Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: implications for cardiovascu-lar disease. Frontiers in immunology, v. 6, p. 477, 2015.
21. MILLER et al. New and emerging drugs and tar-gets for type 2 diabetes: reviewing the evidence. American health & drug benefits, v. 7, n. 8, p. 452, 2014.
22. LU et al. Type 2 diabetes study, introduction and perspective. The Open Diabetes Journal, v. 8, n. 1, 2018.
23. DESHMUKH et al. Investigation of known esti-mated glomerular filtration rate loci in patients with type 2 diabetes. Diabetic medicine, v. 30, n. 10, p. 1230-1235, 2013.
24. GOHIL, Kunj; ENHOFFER, Devin. Diabetes mar-ket grows ever more crowded. Pharmacy and Thera-peutics, v. 39, n. 12, p. 877, 2014.
25. HAN, Bei et al. Design, synthesis and primary ac-tivity of thiomorpholine derivatives as DPP-IV inhibi-tors. Chinese Chemical Letters, v. 23, n. 3, p. 297-300, 2012.
26. JADAV, Pradip et al. Long-acting peptidomimet-ics based DPP-IV inhibitors. Bioorganic & medicinal chemistry letters, v. 22, n. 10, p. 3516-3521, 2012.
27. GALSTYAN, Karina Oganesovna et al. First Rus-sian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients. Dia-betes mellitus, v. 19, n. 1, p. 89-96, 2015.
28. ALI, Zulphikar et al. Design and synthesis of quinazoline-3, 4-(4H)-diamine endowed with thiazoline moiety as new class for DPP-4 and DPPH inhibitor. Bioorganic chemistry, v. 71, p. 181-191, 2017.
29. HUAN, Yi et al. The dual DPP4 inhibitor and GPR119 agonist HBK001 regulates glycemic control and beta cell function ex and in vivo. Scientific re-ports, v. 7, n. 1, p. 1-11, 2017.
30. LI, Ning et al. Design, synthesis and biological evaluation of novel pyrimidinedione derivatives as DPP-4 inhibitors. Bioorganic & medicinal chemistry letters, v. 28, n. 12, p. 2131-2135, 2018.
31. MURAGE, Eunice N. et al. Development of po-tent glucagon-like peptide-1 agonists with high en-zyme stability via introduction of multiple lactam bridges. Journal of medicinal chemistry, v. 53, n. 17, p. 6412-6420, 2010.
32. FREMAUX, Juliette et al. Peptide-oligourea hy-brids analogue of GLP-1 with improved action in vi-vo. Nature communications, v. 10, n. 1, p. 1-9, 2019.
33. SANFORD, Mark. Dulaglutide: first global ap-proval. Drugs, v. 74, n. 17, p. 2097-2103, 2014.
34. NORDISK, A. S. Tablet Formulation Comprising Semaglutide and a Delivery Agent. US9993430B2. US Patent, 2018.
35. PLOSKER, Greg L. Dapagliflozin. Drugs, v. 72, n. 17, p. 2289-2312, 2012.
36. POOLE, Raewyn M.; DUNGO, Rosselle T. Ipragli-flozin: first global approval. Drugs, v. 74, n. 5, p. 611-617, 2014.
37. JESUS, Ana R. et al. Targeting type 2 diabetes with C-glucosyl dihydrochalcones as selective sodi-um glucose co-transporter 2 (SGLT2) inhibitors: syn-thesis and biological evaluation. Journal of medicinal chemistry, v. 60, n. 2, p. 568-579, 2017.
38. NG, Wai-Lung et al. Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhi-bition. Scientific reports, v. 7, n. 1, p. 1-8, 2017.
39. CHU, Kuang-Feng et al. Synthesis and biological evaluation of N-glucosyl indole derivatives as sodi-um-dependent glucose co-transporter 2 inhibitors. Bioorganic chemistry, v. 83, p. 520-525, 2019.
40. WANG, Yibing et al. Design, synthesis and bio-logical evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. European journal of medicinal chemistry, v. 180, p. 398-416, 2019.
41. HUSSAIN, Shazia; CHOWDHURY, Tahseen A. The impact of comorbidities on the pharmacological management of type 2 diabetes mellitus. Drugs, v. 79, n. 3, p. 231-242, 2019.
42 XIE, Jianwei et al. Pyrrolo [2, 3-c] azepine deriva-tives: a new class of potent protein tyrosine phos-phatase 1B inhibitors. Bioorganic & medicinal chem-istry letters, v. 21, n. 14, p. 4306-4309, 2011.
43. MATSUMOTO, K.; YOSHITOMI, T.; SHIMADA, T. The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, v. 152, n. 3, p. 119-124, 2018.
44. WILLSKY, Gail R. et al. Anti-diabetic effects of a series of vanadium dipicolinate complexes in rats with streptozotocin-induced diabetes. Coordination chemistry reviews, v. 255, n. 19-20, p. 2258-2269, 2011.
45. NAVARRETE-VAZQUEZ, Gabriel et al. Synthe-sis, in vitro and in silico screening of ethyl 2-(6-substituted benzo [d] thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B in-hibitors. European journal of medicinal chemistry, v. 53, p. 346-355, 2012.
46. YOSHIKAWA, Yutaka; YASUI, Hiroyuki. Zinc complexes developed as metallopharmaceutics for treating diabetes mellitus based on the bio-medicinal inorganic chemistry. Current topics in medicinal chemistry, v. 12, n. 3, p. 210-218, 2012.
47. QIAN, Mengdan et al. Structural basis of fuller-ene derivatives as novel potent inhibitors of protein tyrosine phosphatase 1B: insight into the inhibitory mechanism through molecular modeling studies. Journal of chemical information and modeling, v. 56, n. 10, p. 2024-2034, 2016.
49. ZHI, Ying et al. 4-Quinolone-3-carboxylic acids as cell-permeable inhibitors of protein tyrosine phos-phatase 1B. Bioorganic & medicinal chemistry, v. 22, n. 14, p. 3670-3683, 2014.
50. TRIPATHI, Indra Prasad et al. Synthesis, charac-terization of some antidiabetic copper complexes with ethylenediamine. Research Journal of Chemical Sciences, v. 2231, p. 606X, 2013.
51. VERMA, Mansi et al. Protein tyrosine phospha-tase 1B inhibitors as antidiabetic agents–A brief re-view. Bioorganic chemistry, v. 70, p. 267-283, 2017.
52. PONTIROLI, A. E. Type 2 diabetes mellitus is be-coming the most common type of diabetes in school children. Acta diabetologica, v. 41, n. 3, p. 85-90, 2004.
50. HIDALGO-FIGUEROA, Sergio et al. Synthesis and evaluation of thiazolidine-2, 4-dione/benzazole derivatives as inhibitors of protein tyrosine phospha-tase 1B (PTP-1B): Antihyperglycemic activity with molecular docking study. Biomedicine & Pharma-cotherapy, v. 107, p. 1302-1310, 2018.
51. RATZIU, Vlad et al. Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology, v. 150, n. 5, p. 1147-1159. e5, 2016.
52. EGAN, Aoife; VELLA, Adrian. TTP399: an inves-tigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes. Expert opinion on investigational drugs, v. 28, n. 9, p. 741-747, 2019.
53. GOPALAKRISHNAN, Veerasamy; IYYAM PILLAI, Subramanian; SUBRAMANIAN, Sorimuthu Pillai. Syn-thesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 di-abetes in rats. Biochemistry research international, v. 2015, 2015.
54. VIAL, Guillaume et al. Imeglimin normalizes glu-cose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes, v. 64, n. 6, p. 2254-2264, 2015.
55. VUYLSTEKE, Valerie et al. Imeglimin: a potential new multi-target drug for type 2 diabetes. Drugs in R&D, v. 15, n. 3, p. 227-232, 2015.
56. MCKILLOP et al., Metabolic effects of orally ad-ministered small-molecule agonists of GPR55 and GPR119 in multiple low-dose streptozotocin-induced diabetic and incretin-receptor-knockout mice. Dia-betologia, v. 59, n. 12, p. 2674-2685, 2016.
57. FALA, Loretta. Nesina, Kazano, and Oseni: Three Alogliptin-Based agents approved for treatment of type 2 diabetes. American Health & Drug Benefits, v. 7, p. 127-133, 2014.
58. NISHO, Shinya; ABE, Mariko; ITO, Hiroyuki. Anagliptin in the treatment of type 2 diabetes: safe-ty, efficacy, and patient acceptability. Diabetes, metabolic syndrome and obesity: targets and thera-py, v. 8, p. 163, 2015.
59. ZHENG, Jing-Wei; MA, Lin. Metal complexes of anthranilic acid derivatives: a new class of non-competitive α-glucosidase inhibitors. Chinese Chem-ical Letters, v. 27, n. 5, p. 627-630, 2016.
60. SHARMA, Radhika; SOMAN, Shubhangi S. De-sign and synthesis of novel diamide derivatives of glycine as antihyperglycemic agents. Synthetic Communications, v. 46, n. 15, p. 1307-1317, 2016.
61. XU, Guozhang et al. Discovery of potent and orally bioavailable indazole-based glucagon receptor antagonists for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters, v. 29, n. 20, p. 126668, 2019.
62. HUSSAIN, Hidayat et al. Protein tyrosine phos-phatase 1B (PTP1B) inhibitors as potential anti-diabetes agents: patent review (2015-2018). Expert opinion on therapeutic patents, v. 29, n. 9, p. 689-702, 2019.
63. LIU, Yang et al. Synthesis and biological evalua-tion of novel benzyl-substituted (S)-phenylalanine de-rivatives as potent dipeptidyl peptidase 4 inhibitors. Bioorganic & medicinal chemistry, v. 21, n. 18, p. 5679-5687, 2013.
64. ZHAO, Guohua et al. Substituted piperidinyl glycinyl 2-cyano-4, 5-methano pyrrolidines as potent and stable dipeptidyl peptidase IV inhibitors. Bioor-ganic & medicinal chemistry letters, v. 23, n. 6, p. 1622-1625, 2013.
65. FANG, Yuanying et al. Design and synthesis of novel pyrimido [5, 4-d] pyrimidine derivatives as GPR119 agonist for treatment of type 2 diabetes. Bioorganic & medicinal chemistry, v. 26, n. 14, p. 4080-4087, 2018.
66. YOSHIDA, Tomohiro et al. Fused bicyclic het-eroarylpiperazine-substituted L-prolylthiazolidines as highly potent DPP-4 inhibitors lacking the electro-philic nitrile group. Bioorganic & medicinal chemistry, v. 20, n. 16, p. 5033-5041, 2012.
67. SCHWEHM, Carolin et al. Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold. ACS medicinal chemistry letters, v. 6, n. 3, p. 324-328, 2015.
68. KAUSHIK, N.; KUMAR, N.; KUMAR, A. Synthe-sis, Antioxidant and Antidiabetic Activity of 1-[(5-Substituted phenyl)-4, 5-dihydro-1H-pyrazol-3-yl]-5-phenyl-1H-tetrazole. Indian Journal of Pharmaceutical Sciences, v. 78, n. 3, p. 352-359, 2016.
69. HAN, Bei et al. Design, synthesis and primary ac-tivity of thiomorpholine derivatives as DPP-IV inhibi-tors. Chinese Chemical Letters, v. 23, n. 3, p. 297-300, 2012.
70. TERAUCHI, Yasuo et al. Efficacy and safety of the G protein‐coupled receptor 119 agonist DS‐8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo‐controlled study. Jour-nal of diabetes investigation, v. 9, n. 6, p. 1333-1341, 2018.
71. TAN, Xueying; HU, Jingbo. Evogliptin: a new di-peptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy, v. 17, n. 9, p. 1285-1293, 2016.
72. HASEGAWA, Futoshi et al. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists. Bioorganic & medicinal chemistry let-ters, v. 24, n. 17, p. 4266-4270, 2014.
73. KIM, Jin Hee et al. 1162-P: DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by In-hibiting Hepatic Gluconeogenesis and Enhancing In-sulin Secretion via Stimulation of GLP-1 Secretion. 2019.
74. MU, James et al. Anti-diabetic efficacy and im-pact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonist. PloS one, v. 7, n. 11, 2012.
75. ITO, Yuma et al. Therapeutic effects of the allo-steric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via en-hancements in insulin and leptin signaling in mice. Journal of pharmacological sciences, v. 137, n. 1, p. 38-46, 2018.
76. MCGILL, Janet B. Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials. Thera-peutic advances in endocrinology and metabolism, v. 3, n. 4, p. 113-124, 2012.
77. GUZMAN, Cristina B. et al. Treatment with LY 2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, v. 19, n. 11, p. 1521-1528, 2017.
78. DANG, Qun; VAN POELJE, Paul D.; ERION, Mark D. The Discovery and Development of MB07803, a Second-Generation Fructose-1, 6-bisphosphatase Inhibitor with Improved Pharmacoki-netic Properties, as a Potential Treatment of Type 2 Diabetes. In: New Therapeutic Strategies for Type 2 Diabetes. 2012. p. 306-323.
79. BIFTU, Tesfaye et al. Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. 2014.
80. BERGENSTAL, Richard et al. Eficácia e segurança do taspoglutídeo versus sitagliptina no diabetes mellitus tipo 2 (ensaio T-Emerge 4). Diabe-tes Ther 3, 13 (2012).
81. SCOTT, Lesley J. Teneligliptin: a review in type 2 diabetes. Clinical drug investigation, v. 35, n. 11, p. 765-772, 2015.
82. SINGH, Awadhesh Kumar. Efficacy and safety of teneligliptin. Indian journal of endocrinology and me-tabolism, v. 21, n. 1, p. 11, 2017.
83. MCKEAGE, Kate. Trelagliptin: first global ap-proval. Drugs, v. 75, n. 10, p. 1161-1164, 2015.
84. ZHAO, Peishen et al. Activation of the GLP-1 re-ceptor by a non-peptidic agonist. Nature, p. 1-5, 2020.
85. RAJPUT, Rashmi; PRAKASH, Anupam; AG-GARWAL, Ramesh. Newer Antidiabetic Drugs in the Pipeline. Diabetes management, v. 18, p. 06, 2019.
86. PARK, Yoo Hoi et al. YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model. Archives of pharmacal research, v. 40, n. 6, p. 772-782, 2017.
87. TYURENKOV, Ivan N. et al. ZB-16, a novel gPr119 agonist, relieves the severity of streptozoto-cin–nicotinamide-induced Diabetes in rats. Frontiers in endocrinology, v. 8, p. 152, 2017.